L3VLUP
ProSign in

ONC · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ONCJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ONC
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterONCJNJ
Q3 20205 holders, $2.9bn30 holders, $26.2bn
Q4 20209 holders, $2.9bn32 holders, $26.6bn
Q1 20219 holders, $4.7bn31 holders, $25.3bn
Q2 20219 holders, $4.2bn37 holders, $25.6bn
Q3 20216 holders, $4.4bn40 holders, $24.1bn
Q4 20216 holders, $3.2bn33 holders, $25.2bn
Q1 20224 holders, $2.0bn35 holders, $28.2bn
Q2 20224 holders, $1.5bn33 holders, $26.9bn
Q3 20225 holders, $1.2bn36 holders, $25.4bn
Q4 20226 holders, $2.1bn35 holders, $27.6bn
Q1 20237 holders, $1.8bn42 holders, $24.5bn
Q2 20236 holders, $1.5bn38 holders, $25.0bn
Q3 20234 holders, $1.7bn37 holders, $18.9bn
Q4 20232 holders, $1.0bn31 holders, $19.0bn
Q1 20244 holders, $926m32 holders, $19.7bn
Q2 20247 holders, $949m35 holders, $20.4bn
Q3 20247 holders, $1.6bn28 holders, $22.3bn
Q4 20244 holders, $1.3bn37 holders, $20.4bn
Q1 202514 holders, $3.4bn32 holders, $20.5bn
Q2 20256 holders, $1.3bn31 holders, $18.4bn
Q3 20258 holders, $2.1bn32 holders, $23.7bn
Q4 20259 holders, $1.8bn29 holders, $27.8bn
Q1 20269 holders, $2.1bn34 holders, $35.6bn
Q2 202612 holders, $2.5bn33 holders, $39.1bn
ONC

Beone Medicines LTD

Holders
14
Reported value
$3.4bn
Buyers
12
Sellers
2

Breadth +10 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$20.5bn
Buyers
16
Sellers
15

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ONC (8)

Artisan Partners LP, Baillie Gifford & Co, Citadel Advisors LLC, Farallon Capital Management LLC, Point72 Asset Management LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Walleye Capital LLC

Only JNJ (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Wellington Management Group LLP, Winton Group Ltd, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →